SOURCE: Novo Nordisk A/S

February 08, 2010 11:08 ET

Novo Nordisk A/S - Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - February 8, 2010) -

Novo Nordisk A/S - Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.

Since the announcement as of 2 February 2010, the following transactions have been made under the programme:

                   Number of     Average      Transaction value,
                    shares    purchase price         DKK
2 February 2010    165,000      368.1829         60,750,179
3 February 2010     90,000      374.2699         33,684,291
4 February 2010     90,000      378.6587         34,079,283
5 February 2010     90,000      375.1000         33,759,000
Accumulated under
the programme      435,000                      162,272,753

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 1,381,775 B shares in the period from 2 February 2010 to 5 February 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 31,191,170 treasury shares, corresponding to 5.0% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

Company Announcement no 7 2010:

Contact Information

  • Further information:


    Elin K Hansen
    Tel: (+45) 4442 3450
    Email Contact

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316
    Email Contact


    Klaus Bülow Davidsen
    Tel: (+45) 4442 3176
    Email Contact

    Kasper Roseeuw Poulsen
    Tel: (+45) 4442 4471
    Email Contact

    In North America:
    Hans Rommer
    Tel: (+1) 609 919 7937
    Email Contact